Oura faces lawsuit accusing it of misleading consumers about sleep-tracking accuracy
Smart ring maker Oura is facing a proposed class action lawsuit alleging it misled consumers about the accuracy of its sleep-tracking features. Filed on Thursday by Clarkson Law Firm in San Francisco, the complaint claims Oura rings cannot actually measure the physiological signals needed to assess sleep quality or stages, relying instead on AI-generated estimates that the lawsuit says have "a coin flip's chance of being correct." This matters because Oura markets its rings, priced from $300, as offering clinical-grade insight into sleep, and the case comes after years of users complaining online that the device's readings did not match how they actually felt.
The lawsuit argues that determining sleep stages genuinely requires equipment such as scalp electrodes and eye sensors found only in clinical settings, since "sleep happens in the brain, not on one's finger." It alleges Oura advertised "unparalleled accuracy," at one point citing 79% accuracy and more recently claiming 95% sleep-staging accuracy versus clinical sleep labs. The complaint seeks an injunction to stop the company misrepresenting its products, along with restitution for affected customers. Oura had not responded to a request for comment at the time of publication.
- Oura sued over claims its rings can't accurately track sleep stages
- Class action alleges AI estimates replace real physiological measurement
- Lawsuit seeks injunction and restitution for affected customers
New here? Start with this
Oura is a company that sells smart rings worn on the finger. The rings use sensors and software to estimate information about a wearer’s health, including how long they sleep and which stages of sleep they may pass through.
Sleep stages are usually assessed in clinical sleep studies using sensors that record signals from the brain and eyes, as well as other parts of the body. Consumer wearables estimate them from signals they can measure at the wrist or finger, so their readings may differ from clinical measurements.
The dispute matters to people deciding whether to buy a ring partly for its sleep information, and to customers who rely on its estimates. It centres on what Oura says its product can measure and how accurately it can do so.
Both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Oura might reasonably argue that whilst its rings cannot replicate clinical laboratory conditions, they provide useful estimates of sleep patterns through movement detection and biometric analysis. The company could point to validation studies supporting its accuracy claims and note that many consumers knowingly purchase wearable devices understanding they deliver estimates rather than clinical-grade measurement; users nonetheless derive genuine value in tracking sleep trends and identifying patterns. The lawsuit may overstate the limitations of the device whilst discounting the practical benefit it provides.
The case against
The lawsuit presents the case that Oura's marketing constitutes material deception. If the technology genuinely cannot measure the physiological signals necessary for clinical-grade sleep staging, then advertising "unparalleled accuracy" alongside specific percentage claims (79%, 95%) directly misrepresents the device's capabilities. Marketing a $300 product as offering clinical-grade insight whilst relying on AI estimates with minimal advantage over chance appears to violate consumer trust, particularly given users reported that readings did not match their actual sleep experience.